MEDCO CONTAINMENT SERVICES SENIOR EXEC VP-SALES DONALD DAHLIN
Executive Summary
MEDCO CONTAINMENT SERVICES SENIOR EXEC VP-SALES DONALD DAHLIN joins the firm from PCS, where he was president and chief executive officer. Medco created the new position for Dahlin, who will report to Chairman and President Martin Wygod. Dahlin, 38, moved to Medco Aug. 10, the date Medco announced his appointment. He disclosed his intention to resign from McKesson's Pharmaceutical Card Service subsidiary in mid-June. Dahlin had been PCS' chief executive since 1981. McKesson is said to be considering either a divestiture of PCS or an increase in its 86% equity interest ("The Pink Sheet" Aug. 7, p. 14). Both PCS and Medco are expected to bid for a drug claims processing contract under the Medicare catastrophic care program. Medco operates Paid Prescriptions drug claims processing business and National Rx mail service pharmacies. Medco's Wygod said the addition of Dahlin "to Medco's management team will greatly strengthen its ability to design, develop, and implement prescription drug programs that lower prescription drug costs to employers, insurance companies, unions and HMOs."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth